Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

American Association of Pharmaceutical

American Academy of Environmental Medicine (AAEM), 277 American Association for Aerosol Research (AAAR), 267 American Association of Pharmaceutical Scientists (AAPS), 267 American Association of Poison Control Centers (AAPCC), 277 American Association of Radon Scientists and Technologists (AARST), 267... [Pg.320]

Zentner, G. M., Pogany, S. A., Sparer, R. V., Shih, C., and Kaul, F., The design, fabrication and performance of acid catalyzed poly(ortho ester) erodible devices. Abstracts of the Third Annual Meeting. American Association of Pharmaceutical Scientists. Orlando, FL, 1988. [Pg.160]

TA Hicks, B Patel, LL Augsburger, R Shangraw, L Lesko, V Shah, D Young. The effect of relative magnitudes of absorption and elimination half-lives on the decision of Cmax-based bioequivalence (abstr). American Association of Pharmaceutical Scientists, 8th Annual Meeting, Orlando, FL, November 1993. [Pg.383]

A number of alternative sizing methods are available, and these are described in Table 8. The American Association of Pharmaceutical Scientists, Inhalation Focus Group conducted a comprehensive review of available methods, which was published in a series of articles identified in the last column of the table. All of the methods described either have been or are currently employed in the development of aerosol products. However, at this time only the inertial samplers, cascade impactors and impingers appear in compendial standards and in regulatory guidelines [44-46], Other methods such as thermal imaging are also under development and may give complementary size information to the current methods. [Pg.497]

White, R.E., in Pharmaceutical Profiling in Drug Discovery for Lead Selection, Borchardt, R.T., Ed., 2004, American Association of Pharmaceutical Scientists Press, p. 431. [Pg.228]

Library of Congress Control Number 2007937951 2008 American Association of Pharmaceutical Scientists... [Pg.703]

Dobetti L, Pantaleo V. Hydrod5mamics in microencapsulation by coacervation. American Association of Pharmaceutical Scientists, Annual Meeting and Exposition, Indianapolis, IN, October 29-November 2, 2000. [Pg.126]

American Association of Pharmaceutical Scientists (A APS). A APS conferences (e.g., the Arden House Conference) and workshops provided help in defining the desired state. An AAPS PAT focus group has been established. [Pg.513]

MICHAEL LEVIN is President and CEO, Metropolitan Computing Corporation (MCC), East Hanover, New Jersey, specializing in process analytical instrumentation as well as data acquisition and control systems for tablet presses, mixers, roller compactors, and other equipment. Prior to forming MCC in 1985, he was a consultant to pharmaceutical companies such as Merck, Sandoz, and Warner-Lambert. A member of the American Association of Pharmaceutical Scientists, the International Society for Pharmaceutical Engineering, and the Biomedical Engineering Society, Dr. Levin received the Ph.D. degree (1985) in biomathematics from the University of Washington, Seattle. [Pg.539]

Chen MC, Huang S-M, Mozersky R, Beitz J, Honig P. Drug interactions involving St. John s Wort-data from FDA s adverse reaction reporting system. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Denver CO, October 2001. [Pg.274]

Wei X, Park M, Ahn H. American Association of Pharmaceutical Scientists Fourth Annual Meeting and Exposition, New Orleans, November 14, 1999. [Pg.274]

Michael J. Groves, a pharmacist with a doctorate in chemical engineering, has spent much of his career working in industry and academe. Now retired, his scientific interests include dispersed drug delivery systems and quality control issues for parenteral drug products. Editor or joint editor of a number of books, he has published 400 research papers, patents, reviews, and book reviews. He is a Fellow of the Royal Pharmaceutical Society of Great Britain, the Institute of Biology, and the American Association of Pharmaceutical Scientists. [Pg.403]

During the 1990 Washington Conference on Analytical Methods Validation Bioavailability, Bioequivalence and Pharmacokinetic Studies [1], parameters that should be used for method validation were defined. The final report of this conference is considered the most comprehensive document on the validation of bioanalytical methods. Many multinational pharmaceutical companies and contract research organizations contributed to its final draft. This scientific meeting was sponsored by the American Association of Pharmaceutical Scientists (AAPS), the Association of Official Analytical Chemists (AOAC), and the U.S. Food and Drug Administration (FDA). The conference report has been used as a reference by bioanalytical laboratories and regulatory agencies worldwide. [Pg.106]

This guidance is the result of 1) a workshop on the scale-up of immediate release drug products conducted by the American Association of Pharmaceutical Scientists in conjunction with the United States Pharmacopoeial... [Pg.353]

Bugge CJL, Crun I, Ljungqvist A, Vatankhan M, Garci DB, Warren HB, Gupta S, American Association of Pharmaceutical Scientists Annual Meeting, Seattle, WA (1996). [Pg.34]

Furthermore, ISPE is in the process of establishing guidance on process transfer. This is the result of a collaboration with the U.S. FDA and the American Association of Pharmaceutical Scientists (AAPS), with input from European regulatory authorities and the Japanese MHLW. This technology transfer guide is designed to present a standardized process and recommends a minimum base of documentation in support of the transfer request. [Pg.874]

Baertschi SW. The Role of Stress Testing in Pharmaceutical Product Development, presented at the American Association of Pharmaceutical Scientists Midwest Regional Meeting, Chicago, IL, May 20, 1996. [Pg.12]

Desselle SP, Rappaport HM. 1995. Feasibility and relevance of identified pharmaceutical care practice standards for community pharmacists. Paper presented at the American Association of Pharmaceutical Scientists Annual Meeting, Miami, FL, November 7. [Pg.16]

Yu, R.Z., J. Matson, and R.S. Geary. 2001. Terminal elimination rates for antisense oligonucleotides in plasma correlate with tissue clearance rates in mice and monkeys. In Annual Meeting of American Association of Pharmaceutical Scientists, Denver, Colorado. [Pg.117]

J. Matson, S. Murray, S. Booten, S. Bhanot, B. Monia, and R.S. Geary. 2003. effect of treatment regimen on sub-organ pharmacodynamics of a 2 -MOE modified anti-sense oligonucleotide, Isis 116847, targeting putative protein tyrosine phosphatase (PTEN) mRNA in rats. In AAPS Annual Meeting and Exposition. American Association of Pharmaceutical Scientists, Salt Lake City, UT. [Pg.118]

Kovar, A., and B. Meibohm. 2004. Drug development in oncology. In P. Bonate and D. Howard (Eds.), Pharmacokinetics in Drug Development. Regulatory and Development Paradigms. Volume 2. American Association of Pharmaceutical Scientists Press, Arlington,VA, pp. 281-304. [Pg.370]

Fink, S. W. Rourick, R. A. Whitney, J. L. Volk, K. J. Klohr, S. E. DiDo-nato, G. C. Kerns, E. H. Lee, M. S. 1997. Accelerating drug development using automated predictive stability profiling methodologies. Annual Meeting of the American Association of Pharmaceutical Scientists (Boston, Massachusetts), 590. [Pg.213]

A. DAVID RODRIGUES is Executive Director, Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, NJ, and received his Ph.D. in Biochemistry from the University of Surrey, Guildford, UK. Dr. Rodrigues is a member of the American Association of Pharmaceutical Scientists and is presently serving on the Scientific Affairs Committee of the International Society for the Study of Xenobiotics. He has authored more than 75 peer-reviewed articles and over one dozen book chapters, and sits on the Editorial Board of three journals (Drug Metabolism and Disposition, Drug Metabolism Letters, and Current Drug Metabolism). [Pg.745]

Chang Q, Ibrahim R, Veltri J, Weber C, Sesi N. 2006. Low-dose drug products analytical challenges and strategies. Oral presentation in American Association of Pharmaceutical Scientists Annual Meeting, Nashville, TN. [Pg.281]


See other pages where American Association of Pharmaceutical is mentioned: [Pg.223]    [Pg.267]    [Pg.752]    [Pg.818]    [Pg.819]    [Pg.425]    [Pg.213]    [Pg.399]    [Pg.306]    [Pg.508]    [Pg.72]    [Pg.267]    [Pg.205]    [Pg.328]    [Pg.679]    [Pg.543]    [Pg.739]    [Pg.798]    [Pg.826]    [Pg.643]    [Pg.117]    [Pg.151]    [Pg.14]   


SEARCH



American Association of Pharmaceutical Scientists

Journal of the American Pharmaceutical Association

Pharmaceutical Association

© 2024 chempedia.info